

REMARKS

Examiner rejected claims 26-29 under 35 U.S.C. 102(e) as being anticipated by Xiao et al and Kapeller-Libermann et al. However, the references cited have the filing dates after the applicants' filing date. The rejection was based on claimed priority date (earlier filing date than our application), yet references with the earlier filing dates were never presented. Since the USPTO has the burden to establish prima facie 102(e) evidences, applicants do reserve the right to request for the priority documents for review. However, to expedite the prosecution of the application, applicants have canceled claims 26-29; thus, claims 1-2 and 24-25 are allowable as stated by the previous Office Action.

Applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,

CELERA GENOMICS

By: 

Lin Sun-Hoffman, Ph.D.,
Reg. No. 47,983

Date October 7, 2003

Celera Genomics Corporation
45 West Gude Drive, C2-4#21
Rockville, MD 20850
Tel: 240-453-3628
Fax: 240-453-3084